Abbott Laboratories Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NYSE
John G Stratton, a Director of Abbott Laboratories, received 397 shares of common stock on September 30, 2026.
NYSE
Kevin T Conroy, a Director of Abbott Laboratories, received 318 shares of common stock on September 30, 2026.
NYSE
Nita Ahuja, a Director of Abbott Laboratories, received 318 shares of common stock on September 30, 2026.
NYSE
Michael F Roman, a Director of Abbott Laboratories, received 381 shares of common stock on September 30, 2026.
NYSE
Kevin T Conroy, a Director of Abbott Laboratories, reported a transaction in 52,507 shares of common stock on September 23, 2026.
NYSE
Philip P Boudreau, EVP AND CFO of Abbott Laboratories, reported a transaction in 388 shares of common stock on September 1, 2026.
NYSE
Robert B Ford, CHAIRMAN AND CEO and a Director of Abbott Laboratories, sold 398,832 shares of common stock on August 25, 2026.
NYSE
Louis H. Morrone, EXECUTIVE VICE PRESIDENT of Abbott Laboratories, sold 5,850 shares of common stock on August 11, 2026 for $109.83 per share.
NYSE
Abbott Laboratories Director John G. Stratton reported a transaction involving stock equivalent units on June 30, 2026.
NYSE
Michael F. Roman, a Director at Abbott Laboratories, acquired stock equivalent units valued at $90.74 per unit on June 30, 2026, as reported in a Form 4 filing.
NYSE
Abbott Laboratories Director Patricia Paola Gonzalez reported transactions involving stock equivalent units, reflecting director fees and dividend reinvestment.
NYSE
Kevin T. Conroy, a Director at Abbott Laboratories, reported the acquisition of 231 stock equivalent units on June 30, 2026, valued at $90.74 per unit.
NYSE
Nita Ahuja, a Director at Abbott Laboratories, reported transactions involving stock equivalent units, reflecting her compensation and investment in the company.
NYSE
Louis H. Morrone, Executive Vice President at Abbott Laboratories, reported a transaction involving the sale of common shares.
NYSE
Abbott Laboratories executive Elizabeth C. Cushman has reported the sale of company common shares.
NYSE
John G. Stratton, a Director at Abbott Laboratories, acquired 2,000 common shares.
NYSE
Mary K. Moreland, Executive Vice President at Abbott Laboratories, acquired 5,314 common shares through a transaction on April 28, 2026.
NYSE
Abbott Laboratories director Kevin T. Conroy was granted 2,286 restricted stock units under the company's 2026 Incentive Stock Program.
NYSE
Abbott Laboratories director John G. Stratton was granted 2,286 restricted stock units under the 2026 Incentive Stock Program.
NYSE
Director Daniel J. Starks acquired 12,286 shares and 7,105 stock options in Abbott Laboratories through recent equity grants and open market purchases.
NYSE
Abbott Laboratories Director Michael F. Roman was granted 2,286 restricted stock units under the 2026 Incentive Stock Program.
NYSE
Abbott Laboratories director Michael O'Grady was granted 2,286 restricted stock units and 5,929 stock options as part of the 2026 Incentive Stock Program.
NYSE
Director Nancy McKinstry received a grant of restricted stock units and stock options as part of the 2026 Incentive Stock Program.
NYSE
Director Darren W. McDew was granted 2,286 restricted stock units under the Abbott Laboratories 2026 Incentive Stock Program.
NYSE
Director Michelle Kumbier was granted 2,286 restricted stock units under the Abbott Laboratories 2026 Incentive Stock Program.
NYSE
Director Patricia Paola Gonzalez was granted 2,286 restricted stock units under the Abbott Laboratories 2026 Incentive Stock Program.
NYSE
Director Sally E. Blount was granted 2,286 restricted stock units under the Abbott Laboratories 2017 Incentive Stock Program.
NYSE
Abbott Laboratories Director Claire Babineaux-Fontenot was granted 2,286 restricted stock units under the 2026 Incentive Stock Program.
NYSE
Abbott Laboratories Director Nita Ahuja was granted 2,286 restricted stock units under the company's 2026 Incentive Stock Program.
NYSE
Abbott Laboratories EVP and CFO Philip Boudreau disclosed the acquisition of company shares through a profit-sharing trust and his spouse.